- Home
- DLTH vs ATOS Comparison
DLTH vs ATOS Comparison
Compare DLTH & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLTH
- ATOS
- Stock Information
- Founded
- DLTH 1989
- ATOS 2009
- Country
- DLTH United States
- ATOS United States
- Employees
- DLTH N/A
- ATOS N/A
- Industry
- DLTH Clothing/Shoe/Accessory Stores
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- DLTH Consumer Discretionary
- ATOS Health Care
- Exchange
- DLTH Nasdaq
- ATOS Nasdaq
- Market Cap
- DLTH 104.5M
- ATOS 96.8M
- IPO Year
- DLTH 2015
- ATOS 2012
- Fundamental
- Price
- DLTH $1.74
- ATOS $0.67
- Analyst Decision
- DLTH Hold
- ATOS Strong Buy
- Analyst Count
- DLTH 1
- ATOS 3
- Target Price
- DLTH $2.75
- ATOS $7.00
- AVG Volume (30 Days)
- DLTH 68.6K
- ATOS 516.6K
- Earning Date
- DLTH 03-13-2025
- ATOS 03-25-2025
- Dividend Yield
- DLTH N/A
- ATOS N/A
- EPS Growth
- DLTH N/A
- ATOS N/A
- EPS
- DLTH N/A
- ATOS N/A
- Revenue
- DLTH $626,629,000.00
- ATOS N/A
- Revenue This Year
- DLTH $4.57
- ATOS N/A
- Revenue Next Year
- DLTH N/A
- ATOS N/A
- P/E Ratio
- DLTH N/A
- ATOS N/A
- Revenue Growth
- DLTH N/A
- ATOS N/A
- 52 Week Low
- DLTH $1.58
- ATOS $0.66
- 52 Week High
- DLTH $5.00
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- DLTH 24.26
- ATOS 34.82
- Support Level
- DLTH $2.07
- ATOS $0.66
- Resistance Level
- DLTH $3.08
- ATOS $0.77
- Average True Range (ATR)
- DLTH 0.18
- ATOS 0.04
- MACD
- DLTH -0.05
- ATOS 0.00
- Stochastic Oscillator
- DLTH 11.43
- ATOS 11.73
About DLTH Duluth Holdings Inc. Class B
Duluth Holdings Inc is an apparel brand in the United States. The company offers shirts, pants, and casual wear for men and women under brands like Alaskan Hardgear, Armachillo, Ballroom, Cab Commander, Crouch Gusset, Dry on the Fly, Duluth Trading Co, Duluthflex, Fire Hose, Longtail T, No Polo Shirt, No Yank, Wild Boar Mocs, and others. The Company's revenue consists of the sale of apparel, footwear, and hard goods. The company operates in a single operating segment.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.